For the current week, the overall ratings of four biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Ironwood Pharmaceuticals, Inc. Class A (IRWD) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Ironwood Pharmaceuticals discovers, develops, manufactures, and commercializes marketed drugs. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Equity, Cash Flow and Sales Growth, IRWD also gets F’s. As of Jan. 15, 2014, 18.5% of outstanding Ironwood Pharmaceuticals, Inc. Class A shares were held short. For more information, get Portfolio Grader’s complete analysis of IRWD stock.
Trius Therapeutics, Inc.’s (TSRX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.
Peregrine Pharmaceuticals, Inc. (PPHM) experiences a ratings drop this week, going from last week’s C to a D. Peregrine Pharmaceuticals is a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at PPHM, get Portfolio Grader’s complete analysis of PPHM stock.
BioTime, Inc. (BTX) gets weaker ratings this week as last week’s C drops to a D. BioTime is a biotechnology company that focuses on regenerative medicine and blood plasma volume expanders. The stock gets F’s in Equity, Cash Flow and Sales Growth. For more information, get Portfolio Grader’s complete analysis of BTX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.